The Impact of P‐Glycoprotein on CNS Drug Efflux and Variability in Response
Journal of Biochemical and Molecular Toxicology · 2025-03 · 39 (3)
DOI: 10.1002/jbt.70190 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Biochemical and Molecular Toxicology, online erschienen am 23.02.2025. Verfasst von Priyanka R Paul und 6 weiteren Autor:innen. Beteiligte Einrichtung: Genomics and Molecular Medicine Unit, Institute of Genomics and Integrative Biology (IGIB), Council of Scientific and Industrial Research (CSIR), New…. Hauptthemen laut MEDLINE: Blood-Brain Barrier, ATP Binding Cassette Transporter, Subfamily B, Member 1, Central Nervous System Agents, Brain. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 137 Literaturangaben. Gefördert von: This work was financially supported by CSIR-Institute of Genomics and Integrative Biology under grant number OLP2301..
Abstract (Originalsprache)
Resistance against CNS drugs may arise from various mechanisms, with limited drug penetration across the blood‐brain barrier (BBB) being a significant contributing factor. The BBB employs efflux transporters like P‐glycoprotein (P‐gp) to safeguard the brain by removing toxins and xenobiotics, however, P‐gp also pumps out therapeutic drugs, and its upregulation in disease states can contribute to variability in drug response. While inhibiting P‐gp to prevent drug efflux seems appealing, it could lead to toxicity since P‐gp is also important for expulsion of toxins from the brain. This necessitates the incorporation of P‐gp substrate liability assessment into early drug discovery stages using appropriate experimental approaches. Therefore, this review aims to draw interest in this crucial area by analyzing the existing research on P‐gp's impact on brain distribution of major CNS drugs and exploring the detection methods for identifying P‐gp substrates. By identifying confirmed P‐gp substrates and evaluating effective detection methods, this work emphasizes the continued importance of monitoring P‐gp‐mediated CNS drug efflux out of the brain tissue. This knowledge can empower clinicians to anticipate potential treatment inefficacy and guide therapeutic decision‐making, ultimately leading to improved patient treatment outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Genomics and Molecular Medicine Unit, Institute of Genomics and Integrative Biology (IGIB), Council of Scientific and Industrial Research (CSIR), New Delhi, India.
- Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India.
- Department of Biotechnology, Delhi Technological University, New Delhi, India.
- Department of Chemistry, Hindu College, University of Delhi, New Delhi, India.
- Nucleic acid research lab, Department of Chemistry, University of Delhi, New Delhi, India.
Förderung
- This work was financially supported by CSIR-Institute of Genomics and Integrative Biology under grant number OLP2301.
Zitieren
APA
Paul, P. R., Mishra, M. K., Bora, S., Kukal, S., Singh, A., Kukreti, S., & Kukreti, R. (2025). The Impact of P‐Glycoprotein on CNS Drug Efflux and Variability in Response. Journal of Biochemical and Molecular Toxicology, 39(3). https://doi.org/10.1002/jbt.70190
Vancouver
Paul PR, Mishra MK, Bora S, Kukal S, Singh A, Kukreti S, et al. The Impact of P‐Glycoprotein on CNS Drug Efflux and Variability in Response. Journal of Biochemical and Molecular Toxicology. 2025;39(3). doi:10.1002/jbt.70190
BibTeX
@article{Paul2025,
author = {Paul, Priyanka R and Mishra, Manish K and Bora, Shivangi and Kukal, Samiksha and Singh, Anju and Kukreti, Shrikant and Kukreti, Ritushree},
title = {The Impact of P‐Glycoprotein on CNS Drug Efflux and Variability in Response},
journal = {Journal of Biochemical and Molecular Toxicology},
year = {2025},
volume = {39},
number = {3},
doi = {10.1002/jbt.70190}
}
EUVIMED